Phase 3 N=30 Stem Cell Transplantation for Sickle Cell Anemia
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
Phase 2 N=30 Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
N/A N=212 Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Phase 1 N=39 Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
Phase 2 N=109 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Anemia, Sickle Cell
Primary: Gardos Channel Activity — -0.0342; 0.0043; 0.1076 mmol/10^13 cells x min — p=0.080
Early Phase 1 N=17 A Dose-Finding Study of AG-348 in Sickle Cell Disease
Sickle Cell Disease
Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants
Early Phase 1 N=22 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia
Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001
N/A N=120 Decision Aid for Therapeutic Options In Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale
N/A N=67 Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: SCD-specific Knowledge — 32.0; 32.0; 33.5; 33 score on a scale
N/A N=51 Cardiovascular Complications of Sickle Cell Disease
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
Phase 2 N=46 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Phase 2 N=10 Decitabine for High-Risk Sickle Cell Disease
Neutropenia · Sickle Cell Disease
Primary: The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study. — 1; 1; 6 Participants
N/A N=1,906 European Sickle Cell Disease Cohort - Hydroxyurea
Sickle Cell Disease
Primary: % of Patient-years With Malignancies — 0.001 % patient-years
Phase 2 N=130 A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Sickle Cell Disease
Primary: Overall Incidence of Treatment Emergent Severe Adverse Events (SAE) — 15; 20 Participants — p=0.19
Phase 2 N=29 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
N/A N=145 Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
Sickle Cell Disease · Sickle Cell Trait · Beta-Thalassemia
Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value — 96.6; 100; 0; 91.3 percentage
Phase 1 N=15 Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Phase 2 N=10 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
Sickle Cell Disease
Primary: Fetal Hemoglobin Level — 8.3 Percentage
Phase 2 N=100 A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Sickle Cell Disease
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 12; 24; 18; 23 Participants
Phase 2 N=37 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Anemia, Sickle Cell
Primary: C-Reactive Protein — 11.4; 6.8 mg/l
N/A N=25 Measurement of Cerebral Blood Flow Using Transcranial Doppler Ultrasound in Children With Sickle Cell Disease
Sickle Cell Disease
Primary: Measurement of Time Average Mean of the Maximum (TAMM) in cm/Sec in Cerebral Arteries Using 2 Different Ultrasound Machines. — 120; 120 cm/sec
N/A N=28 Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach
Sickle Cell Trait
Primary: Acceptability — 11; 8; 11; 8 Participants
Phase 2 N=203 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Phase 2 N=46 High Dose Vitamin D for Sickle Cell Disease
Sickle Cell Disease
Primary: 25 (OH)D in Nmol/L Between Baseline and 6 Months — 55.2; 50.4 nmol/L — p=0.0507
Phase 1 N=11 Aspirin Prophylaxis in Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
N/A N=59 COVID-19 Vaccine Response in Sickle Cell Disease
Sickle Cell Disease · COVID-19
Primary: Antibody Response to COVID-19 Vaccine in Persons With Sickle Cell Disease — 32.155 units per mL
Phase 2 N=36 Losartan to Reverse Sickle Nephropathy
Nephropathy · Sickle Cell Anemia
Primary: Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline — 1; 7; 5 Participants